In summary, we herein found that the TOR inhibitor EVL exhibits synergistic antifungal activity with azoles and AMB when used to treat Aspergillus spp., indicating that the combinations of these pharmaceutical agents may be a more reliable therapeutic option for the treatment of patients with aspergillosis. Here, RORC is linked to aspergillosis.